Omnicell, Inc.

NASDAQ:OMCL

Medical - Healthcare Information Services

Healthcare
$34.66 -1.49%

-$0.58 today

Market cap
$1.59B
Beta
0.96
P/E (TTM)
84.1
EPS (TTM)
$0.45
52W Low $26.85High $55.00

Volume 0.34M

Average 0.57M

OMCL Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Omnicell, Inc.NASDAQ: OMCL

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $8.3M rose 150.7% year over year, ahead of the -74.9% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -51.6% a year.

Context

  • Change in working capital amounted to 0.7% of revenue in FY2025, down 4.5 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +150.7% holds above the trailing-twelve-month pace of -74.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.3M+30829.6% QoQ
Last fiscal yearDec 2025
-$8.33M-114.3% YoY
LTMMar 2026
-$3.35M-74.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+150.7%——
1 year-114.3%——
3-year CAGR-51.6%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(8.33M) USD
Year-over-year change
-114.3%

Change in Working Capital vs competitors

How OMCL compares with its peers on the latest reported figures

  • OMCL's LTM Mar 2026 change in working capital of $3.35M is the 10th largest of the 11 companies compared; the peer median is $9.78M.
  • Its year-over-year change of -74.9% is the 8th highest of 11, against a peer median of +57.8%.
  • Change in working capital amounts to 0.3% of revenue for OMCL, versus a peer median of 3.6%.
OMCL Competitors Peer median
Change in Working Capital for OMCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TXG10x Genomics, Inc.LTM Jun 2026$51.58M +474.0%—8.4%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$42.39M -9.2%+40.6%5.4%
UFPTUFP Technologies, Inc.LTM Jun 2026$38.57M +183.9%-24.4%6.1%
ASTHAstrana Health, Inc.LTM Mar 2026$30.67M +313.3%+16.6%0.9%
SSIISS Innovations International, Inc.LTM Mar 2026$14.37M +64.7%+70.9%29.7%
SDGRSchrödinger, Inc.LTM Sep 2026$13.47M -112.7%—5.0%
PHRPhreesia, Inc.LTM Apr 2026$11.16M +50.9%+53.9%2.3%
PGNYProgyny, Inc.LTM Jun 2026$8.4M -210.7%—0.6%
TDOCTeladoc Health, Inc.LTM Mar 2026$5.93M +123.8%—0.2%
OMCLOmnicell, Inc.LTM Mar 2026$3.35M -74.9%-51.6%0.3%
OMDAOmada HealthLTM Mar 2026$1.57M -87.6%—0.6%
Peer median (excluding OMCL) $9.78M+57.8%+40.6%3.6%

Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income77.85M5.65M(20.37M)12.53M2.05M
Depreciation & Amortization84.93M99.17M95.56M89.76M86.63M
Deferred Income Tax(3.27M)(37.32M)(11.05M)(14.86M)(1.29M)
Stock-Based Compensation53.16M68.25M55.3M39.32M44.5M
Change in Working Capital(3.34M)(73.47M)43.67M58.33M(8.33M)
Accounts Receivables(40.97M)(60.36M)38.74M(5M)41.42M
Inventory(25.7M)(30.12M)38.02M5.39M(11.23M)
Accounts Payables29.08M(7.75M)(17.53M)7.21M(9.28M)
Other Working Capital34.24M24.76M(15.56M)50.73M(29.25M)
Other Non-Cash Items22.48M15.5M17.98M2.64M3.74M
Operating Cash Flow231.81M77.78M181.09M187.72M127.3M
Capital Expenditures(28.97M)(60.74M)(41.47M)(36.46M)(40.42M)
Acquisitions (Net)(354.16M)2.07M000
Purchases of Investments00000
Sales of Investments0(15.35M)0(10.4M)(10.17M)
Other Investing Activities(29.37M)15.35M0(5.93M)(9.78M)
Investing Cash Flow(412.5M)(58.67M)(55.02M)(52.79M)(60.36M)
Debt Repayment00(2.97M)(225.46M)(175M)
Common Stock Issued040.18M23.22M38.58M16.87M
Common Stock Repurchased(16.29M)(52.21M)00(77.6M)
Dividends Paid00000
Other Financing Activities63.65M(8.93M)3.17M(48.7M)17.42M
Financing Cash Flow47.36M(20.95M)23.42M(235.58M)(218.32M)
Effect of Forex Changes(974K)(944K)(1.35M)(1.72M)3.8M
Net Change in Cash(134.3M)(2.79M)148.14M(102.37M)(147.58M)
Free Cash Flow202.84M17.04M139.62M151.26M86.89M

Omnicell, Inc.

NASDAQ:OMCL

Intrinsic Alpha fair value

Locked

Current Price

$34.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.